Wedbush cuts price targets on Beam Therapeutics and Aclaris Therapeutics
Wedbush lowered its Beam Therapeutics target to $28 from $65 and Aclaris Therapeutics to $8 from $10, keeping Outperform ratings on both stocks.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, citing Benzinga, Wedbush analysts reduced their price target on Beam Therapeutics shares to $28 from $65. The firm kept its Outperform rating on the stock.
Separately, Wedbush trimmed its price target on Aclaris Therapeutics to $8 from $10, and also maintained its Outperform rating.
why it matters
Price target changes from individual analysts usually concern specific companies and rarely move the broader market. For investors in biotech shares, such revisions offer a reference point for valuations but do not by themselves change the picture for the sector.
tags
instruments
sources
- Beam Therapeutics Price Target Cut to $28.00/Share From $65.00 by Wedbush — Dow Jones Newswires, 28 October 2026 at 14:05 UTC
- Aclaris Therapeutics Price Target Cut to $8.00/Share From $10.00 by Wedbush — Dow Jones Newswires, 28 October 2026 at 14:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗